Gallium Ga-68 DOTATATE
Also referenced as: Netspot, Ga-68 dotatate
A somatostatin-receptor-targeted radioactive tracer used in PET imaging.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
Netspot is FDA-approved for localization of somatostatin-receptor-positive neuroendocrine tumors in adults and children; it is diagnostic, not a tumor treatment.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A somatostatin-receptor-targeted radioactive tracer used in PET imaging.
Netspot is FDA-approved for localization of somatostatin-receptor-positive neuroendocrine tumors in adults and children; it is diagnostic, not a tumor treatment.
Uptake is not specific to cancer. This diagnostic tracer is different from therapeutic Lu-177 DOTATATE.
Why It's Being Studied
- Neuroendocrine tumor imaging
- Somatostatin receptors
Mechanism of Action
The peptide binds somatostatin receptors, especially SSTR2, and carries gallium-68 so receptor-positive tissue can be imaged.
The peptide binds somatostatin receptors, especially SSTR2, and carries gallium-68 so receptor-positive tissue can be imaged. Uptake is not specific to cancer. This diagnostic tracer is different from therapeutic Lu-177 DOTATATE.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Neuroendocrine tumor imaging
- Somatostatin receptors
- Intravenous diagnostic radiopharmaceutical
Evidence Summary
Human imaging studies establish lesion localization, not tumor destruction or improved survival from the tracer itself.
Higher tiers carry more weight. Filled tiers have evidence for Gallium Ga-68 DOTATATE; tap to read it.
- Human imaging studies establish lesion localization, not tumor destruction or improved survival from the tracer itself.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Human imaging studies establish lesion localization, not tumor destruction or improved survival from the tracer itself.
Reported Adverse Events in Research
- Radiation exposure and false-positive or false-negative results are important limitations.
Limitations of Current Evidence
- Uptake is not specific to cancer. This diagnostic tracer is different from therapeutic Lu-177 DOTATATE.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Gallium Ga-68 DOTATATE | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Intravenous diagnostic radiopharmaceutical | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Gallium Ga-68 DOTATATE — prescribing label